STX17

Across TCGA pan-cancer cohorts, STX17 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated STX17 data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher STX17 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated STX17 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUAD show a favorable association.

UCEC, LUAD, and PDAC are the cancer types where STX17 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.962	0.770	.002	48	view →
LUAD	DFS	Median	III,IV	0.722	0.246	.004	19	view →
PDAC	DFS	Tertile	II,III,IV	0.542	0.280	.004	16	view →
HNSC	DFS	Tertile	III,IV	0.949	0.286	.008	15	view →
LSCC	OS	Tertile	All	0.696	0.883	.018	4	view →
CCRCC	DFS	Median	All	0.911	0.529	.002	3	view →
GBM	OS	Quartile	All	0.989	0.816	.021	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

STX17–UCEC (DFS)

Open the UCEC breakdown →